Upcoming Events

No Current Upcoming Events

> Archived Events


Search Site

 

 

Stock Price: TSX-V

Pacgen Biopharmaceuticals Corporation is a life sciences company focused on the development of novel therapeutics for the treatment of infectious and inflammatory diseases.

The Company’s lead product, PAC-113, is an anti-fungal in a Phase II program for the treatment of oral Candidiasis. Pacgen recently reported positive proof of efficacy results from its Phase I/IIa trial of PAC-113 and initiated a Phase IIb dose-ranging clinical trial in November 2007. Pacgen also has an early stage research program. The most advanced candidate is a peptide therapeutic, PAC-G31P, which is being investigated in preclinical studies for its potential to treat inflammatory disease.


Latest News

April 15, 2008
Pacgen Completes Patient Recruitment for Phase II Dose Ranging Trial of Novel Anti-Fungal Drug

March 17, 2008
Pacgen Closes $903,000 Private Placement Financing

February 29, 2008
Pacgen Reports Third Quarter Financial Results

November 28, 2007
Pacgen Reports Second Quarter Financial Results

> Archived News